Background-Annually, Ϸ80 000 Americans receive guideline-based primary prevention implantable cardioverterdefibrillators (ICDs), but appropriate firing rates are low. Current selection criteria for ICDs rely on left ventricular ejection fraction, which lacks sensitivity and specificity. Because scar-related myocardial tissue heterogeneity is a substrate for life-threatening arrhythmias, we hypothesized that cardiac magnetic resonance identification of myocardial heterogeneity improves risk stratification through (1) its association with adverse cardiac events independent of clinical factors and biomarker levels and (2) its ability to identify particularly high-and low-risk subgroups. Methods and Results-In 235 patients with chronic ischemic and nonischemic cardiomyopathy with a left ventricular ejection fraction of Յ35% undergoing clinically indicated primary prevention ICD implantation, gadolinium-enhanced cardiac magnetic resonance was prospectively performed to quantify the amount of heterogeneous myocardial tissue (gray zone [GZ]) and dense core scar. Serum high-sensitivity C-reactive protein (hsCRP) and other biomarkers were assayed. The primary end point was appropriate ICD shock for ventricular tachycardia/fibrillation or cardiac death, which occurred in 45 (19%) patients at a 3.6-year median follow-up. On univariable analysis, only diuretics, hsCRP, GZ, and core scar were associated with outcome. After multivariable adjustment, GZ and hsCRP remained independently associated with outcome (PϽ0.001).
and may better predict adverse prognosis compared with LVEF. 11, 12 Similar tissue characteristics related to fibrosis can contribute pathophysiologically to malignant ventricular arrhythmias in many forms of nonischemic dilated cardiomyopathy, in which SCD is also an important cause of death. 13 Heart failure (HF) associated with ischemic and nonischemic cardiomyopathy is characterized by systemic inflammation, and elevated proinflammatory marker levels predict increased cardiovascular morbidity and mortality. 14, 15 Recent studies suggest that high-sensitivity C-reactive protein (hsCRP) may specifically predict higher rates of appropriate ICD discharges in patients with prior infarction and low LVEF, 16, 17 even in the absence of acute coronary ischemia or plaque rupture. 16, 18 Possible explanations are that increasing hsCRP levels reflect progressive LV dysfunction and ongoing changes to the underlying substrate that supports arrhythmogenesis or may have direct electrophysiological effects. 16, 18, 19 We sought to prospectively test the hypothesis that the extent of myocardial tissue heterogeneity by CMR-LGE is associated with cardiac arrhythmic outcome independently of or in combination with other clinical factors and cardiac biomarkers, including hsCRP, in a primary prevention cohort of patients with ischemic and nonischemic cardiomyopathy and an LVEF Յ35%. We also sought to determine whether CMR-LGE could differentiate high-risk from low-risk patients in whom ICD insertion might be safely avoided.
Methods

Study Population
This prospective study comprised the CMR imaging arm of the PROSE-ICD (Prospective Observational Study of Implantable Cardioverter Defibrillators), which enrolls patients receiving ICD therapy for primary prevention of SCD. Between November 2003 and December 2010 at the Johns Hopkins Medical Institutions, we approached patients with an LVEF Յ35% (assessed clinically by echocardiography, nuclear scintigraphy, or ventriculography) scheduled for clinically indicated primary prevention ICD insertion based on published guidelines. 20 Exclusion criteria are listed in the onlineonly Data Supplement. We enrolled 235 patients (30% of eligible patients). The reasons for nonenrollment were refusal to participate in research (78% of those nonenrolled), claustrophobia (7%), and insufficient time to schedule the scan before device implantation (15%).
We included patients with ischemic and nonischemic cardiomyopathy. Patients were classified as having nonischemic cardiomyopathy if they had no history of myocardial infarction or revascularization and no coronary artery stenoses Ͼ50% of Ն2 major epicardial vessels or involving the left main or proximal left anterior descending artery. 21 CMR was performed as close in time to ICD insertion as logistically possible (median, 3 days). The study protocol was approved by the Johns Hopkins Hospital Institutional Review Board. All patients gave written informed consent.
Blood Sample Collection and Analysis
Details are outlined in the online-only Data Supplement.
CMR Imaging and Analysis
Details of the CMR protocol were reported previously. 9, 22 Patients were scanned with a 1.5-T whole-body scanner (Signa CV/I or Siemens Avanto). Standard steady-state free precession and postgadolinium inversion-recovery fast gradient-echo sequences were used (online-only Data Supplement).
Images were analyzed using custom research software (Cinetool). Two observers blinded to clinical outcome determined the dichotomous presence or absence of LGE by reviewing all cross-sections. When present, LGE was quantified into core and GZ extents based on published methodology. 9 Core extent comprised all pixels with an SI of Ͼ50% of maximal SI within the hyperenhanced region. GZ extent comprised all pixels with an SI greater than the peak SI in the normal myocardium but Ͻ50% of the maximal SI within the hyperenhanced region. Total hyperenhancement was defined as the sum of the GZ and core extents.
Clinical Follow-Up
Patients were followed prospectively through clinic visits, telephone calls, and medical record review at 3-to 6-month intervals after ICD placement. ICD therapies were programmed at the discretion of the implanting electrophysiologist. Events were independently adjudicated by a committee of board-certified electrophysiologists who reviewed all stored ICD data and were blinded to all clinical, biomarker, and CMR data.
The primary end point was predefined as the first occurrence of (1) appropriate ICD firing for sustained ventricular tachycardia above the programmed ICD rate cutoff (generally 180 beats/min) or ventricular fibrillation or (2) cardiac death. Deaths were classified according to the most proximate cause after review of ICD interrogations, medical records, death certificates, autopsy reports, and eyewitness accounts. Secondary end points included appropriate ICD Data are presented as meanϮSD, n (%), or median (interquartile range). MI indicates myocardial infarction; NYHA, New York Heart Association; ACE, angiotensinconverting enzyme; ARB, angiotensin receptor blocker; LBBB, left bundle branch block; ICD, implantable cardioverter-defibrillator; hsCRP, high-sensitivity C-reactive protein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; LGE, late gadolinium enhancement.
firings alone, antitachycardia pacing therapy, HF hospitalizations, inappropriate device discharges, and device complications. Patients were censored at the time of heart transplant, LV assist device placement, noncardiac death, or last contact.
Statistical Analysis
Baseline characteristics are summarized as means, medians, or proportions and were compared using parametric or nonparametric testing, as appropriate. CMR variables (GZ, core, and total hyperenhancement) were categorized into tertiles according to the etiology of cardiomyopathy to account for different distributions of scar extent in the patients with chronic ischemic cardiomyopathy versus nonischemic cardiomyopathy given the lower average amount of scar in the patients with n nonischemic cadiomyopathy.
For risk analyses, we used Kaplan-Meier curves to estimate the cumulative incidence of events by tertiles of CMR variables and Cox proportional hazards models to estimate hazard ratios (HRs) for outcomes comparing the 2 highest tertiles to the lowest tertile of CMR variables. All Cox models were stratified by etiology of cardiomyopathy to account for different background HRs for ischemic and nonischemic cardiomyopathies. The following variables were studied in univariable Cox models: age, sex, New York Heart Association functional class, duration of cardiomyopathy, cardiac risk factors, medications, electrophysiological characteristics, laboratory values (sodium, potassium, creatinine, N-terminal pro-B-type natriuretic peptide, and hsCRP), and CMR variables (LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass, GZ, core, and total hyperenhancement). For multivariable analyses, we included only variables significantly associated with outcomes in univariable models (PϽ0.05). On post hoc analysis, to facilitate visualization of the data associations, we compared patients in the highest tertiles of both GZ and hsCRP versus the lowest tertiles of both GZ and hsCRP versus combined intermediate groups. The strength of the association of GZ (the only significant CMR variable on multivariable analyses) with outcome was estimated for subgroups defined by other variable categories and displayed as a forest plot. 23 Tests for interaction were calculated by comparing models with and without product terms for the relevant covariates using likelihood ratio tests.
Results were considered statistically significant if PϽ0.05. All analyses were conducted using Stata version 11 statistical software.
Results
Baseline Characteristics
Baseline characteristics of the cohort are presented in Table 1 . Patient age (meanϮSD) was 57Ϯ13 years. The proportion of men and whites was 76% and 71%, respectively. The primary end point occurred in 45 (19%) patients at a median of 1.6 years (range, 0.08 -6.02 years) after enrollment. Median follow-up time in the patients without events was 3.6 years. Two patients were lost to follow-up after 1 and 3.9 years. Of the 45 events, 30 were appropriate ICD firings and 15 were cardiac deaths. Among patients with ICD firings, the average cycle length of the ventricular tachyarrhythmia terminated with ICD countershock therapy was 232Ϯ48 beats/min. All patients were well treated medically for HF. Patients with events tended to smoke, use diuretics, and have higher hsCRP and N-terminal pro-B-type natriuretic peptide levels. Patients with a primary event had slightly lower LVEF (Pϭ0.05) and larger LV volumes (PϽ0.04). Patients with events had significantly larger GZ extents (Pϭ0.003), borderline elevated core extents (Pϭ0.06), and larger total hyperenhancement (Pϭ0.02) because of the GZ contribution.
Ischemic Versus Nonischemic Etiology
Patients with chronic ischemic cardiomyopathy comprised 58% (nϭ137) of the cohort. The etiologies of nonischemic cardiomyopathy were clinically assessed as occurring in the setting of idiopathic causes (nϭ81, 83%), neuromuscular disorders (nϭ5), prior chemotherapy/radiation (nϭ4), history of sarcoidosis (nϭ4), history of myocarditis (nϭ2), peripartum (nϭ1), and scleroderma (nϭ1).
GZ was present in both patients with chronic ischemic cardiomyopathy and patients without nonischemic cardiomyopathy (Figures 1 and 2) . Incidence rates of the primary end point were not statistically different in those with and without chronic ischemic cardiomyopathy (5.6% versus 6.4%, logrank Pϭ0.7), despite differences in baseline characteristics (online-only Data Supplement Table) . On subgroup analysis, the association between GZ-CRP tertiles and outcome remained similar, regardless of cardiomyopathy etiology (online-only Data Supplement Figure I ).
Primary End Point Occurrence
In univariable Cox models, only diuretic use, hsCRP, GZ, core, and total LGE were significantly associated with the primary event ( Table 2) . In multivariable analysis, only diuretic usage, GZ, and hsCRP remained significant. The adjusted HRs comparing the second and third tertiles of GZ to the first tertile were 3.9 (95% CI, 1.2-12.4) and 4.6 (95% CI, 1.4 -15.4), respectively. For hsCRP, the corresponding HRs were 2.4 (95% CI, 0.9 -6.2) and 2.8 (95% CI, 1.1-7.1), respectively.
The combination of GZ and hsCRP was associated with an HR of 24.0 (95% CI, 3.1-184; Pϭ0.002), comparing patients in the highest tertile of both GZ and hsCRP to those in the lowest tertile of both. Moreover, the 42 (18%) patients in the lowest tertiles of both GZ and hsCRP had an extremely low incidence of the primary end point (0.7% per year) compared to 5.6% and 16.1% per year in the middle and highest risk groups ( Figure 3A) . Of the 42 patients in the lowest GZ-hsCRP tertiles, 27 were classified as nonischemic and 15 as ischemic. Image from a 79-year-old man with ischemic cardiomyopathy who sustained a large anterior myocardial infarction with late reperfusion. A, A midventricular short-axis cardiac magnetic resonance cross-section with extensive late gadolinium enhancement of the anterior, anteroseptal, and anterolateral walls (arrows). B, The scarred region predominantly consists of core infarct (red) with a small amount of periinfarct gray zone (yellow). *For the multivariable analysis, because the total LGE is derived partly from gray zone, both were not included in the model.
The positive association between GZ extent and the primary end point persisted across age, sex, race/ethnicity, cardiomyopathy etiology, and hsCRP categories (onlineonly Data Supplement Figure II) . The extent of the association was almost identical in the patients with chronic ischemic and nonischemic cardiomyopathy.
Secondary End Point Occurrence
When assessing only appropriate ICD firings (nϭ30; 4% overall incidence per year), GZ-hsCRP tertiles remained associated with events (log-rank Pϭ0.002) ( Figure 3B ). No ICD firing occurred in the setting of myocardial ischemia or infarction or active myocardial inflammation. The onlineonly Data Supplement contains additional secondary end point results.
Discussion
There are 2 important findings from this prospective study of primary prevention ICDs in patients with reduced LVEF: (1) myocardial scar characteristics, particularly GZ extent, and serum hsCRP were strongly associated with appropriate ICD firings and cardiac death, and (2) a subgroup of patients with small GZ extents and low hsCRP levels had an extremely low risk of events. This novel approach of combining an imaging metric with a serum biomarker for risk stratification is unique in that it may allow for the identification of a subset of patients in whom ICD implantation could possibly be avoided because their annual cardiac event rate (Ͻ1% per year) is comparable to or below the reported ICD-related complication rates. 5 Although this will require further investigation, it is worth pursuing in future prospective trials because reducing the need for unnecessary ICD implantation in as many as 20% of primary prevention candidates could have significant implications at the individual and societal level.
The current study supports a mechanistic role of myocardial tissue heterogeneity in ventricular arrhythmias. Dense, fibrous scar tissue is unable to depolarize and, hence, is incapable of initiating or sustaining arrhythmias. However, if scarred regions are interspersed with surviving muscle bundles, which are able to depolarize, albeit abnormally, tissue heterogeneity may form an arrhythmogenic substrate by regionally slowing conduction and precipitating reentrant phenomena. 13, 24, 25 Although the initiating insults are different in the various forms of cardiomyopathy, they trigger and result in changes in the interstitial matrix that promote myocardial fibrosis, which has been described in various nonischemic forms of cardiomyopathy and appears histologically as varying admixtures of viable myocytes and collagen. 26 -33 Scar-related reentrant ventricular arrhythmias are well described in nonischemic cardiomyopathies and are an important cause of death. 13, 26, 34, 35 The current findings are consistent with prior reports in which the absence of nonischemic scar has been associated with fewer composite major cardiac events in patients with LV dysfunction. 22, 33, 36 
Comparison With Prior CMR-LGE Studies
Previous studies 10 -12 have used CMR-LGE in primary and secondary prevention ICD patients to examine the prognostic value of tissue heterogeneity on cardiovascular and noncardiovascular end points and focused on patients with chronic ischemic cardiomyopathy. Another study 36 of 103 patients included those with and without chronic ischemic cardiomyopathy and reported that LGE presence predicted appropriate ICD therapy at 1.6 years. However, it is unclear how ischemic etiology was defined. Neither total LGE nor tissue heterogeneity was quantified, and the low-risk group was confined to those patients with nonischemic cardiomyopathy and absence of scar.
The current results expand on previously published studies by providing prospective data with longer follow-up duration (median, 3.6 years) in both patients with ischemic cardiomyopathy and patients with nonischemic cardiomyopathy that support the role of increased myocardial tissue heterogeneity in ventricular arrhythmogenesis. More importantly, the unique combined imaging and biomarker strategy proposed here can be applied to both ischemic and nonischemic cardiomyopathy and enables the identification of a very-lowrisk cohort. The GZ tertiles corresponding to low risk were GZ of 0 g in patients without chronic ischemic cardiomyopathy and a maximal GZ cutoff of 8.7 g in patients with chronic ischemic cardiomyopathy. For the highest tertile group, GZ cutoffs were Ն1.7 g in patients without chronic ischemic cardiomyopathy and Ն17.9 g in patients with chronic ischemic cardiomyopathy. The hsCRP cutoffs were Յ1.8 mg/L for the lowest tertile and Ն5.9 mg/L for the highest tertile. hsCRP indicates highsensitivity C-reactive protein; ICD, implantable cardioverter-defibrillator.
hsCRP and SCD Risk
Although hsCRP is an established marker of atherosclerotic heart disease risk and predicts disease severity and outcome in patients with HF, 14 published data are mixed regarding its role in predicting arrhythmic outcomes. 16 -18,37-39 Among healthy men in the Physicians' Health Study, hsCRP was significantly associated with SCD risk over the ensuing 17 years, independent of the occurrence of myocardial infarction. 18 Elevated hsCRP has been associated with an increased risk of appropriate ICD discharges in patients with ischemic LV dysfunction, also independently of acute ischemia/infarction. 16, 17 A recent prospective observational study of 294 patients postinfarction examined whether hsCRP levels of Յ3 versus Ͼ3 mg/L predicted arrhythmic outcomes. 38 Although patients with an hsCRP level of Ͼ3 mg/L did not have a worse prognosis, 37 follow-up was relatively short at 2 years. In the current study, one half of all events occurred Ͼ1.6 years after enrollment. Additionally, whereas the prior study examined a dichotomous hsCRP cutoff of 3 mg/L, we examined tertiles of risk, and the results support a linear increase in risk as hsCRP rises, even at levels of Ͻ3 mg/L, which has been shown in other cohorts. 40 Although the mechanisms linking elevated hsCRP to ventricular arrhythmogenesis are unclear, a potential explanation is the deleterious effects of cytokines in HF. 41, 42 CRP is an acute phase reactant produced in response to cytokines. Proinflammatory cytokines are expressed in the setting of cardiac injury, and their production is enhanced by sympathetic nervous system activation. Thus, progressive LV remodeling and the resulting adverse clinical outcomes likely result, in part, from the deleterious effects of proinflammatory mediators on the existing substrate. Cytokines may cause myocyte apoptosis and necrosis as well as LV dilation through matrix metalloproteinase activation, all of which may accelerate HF progression. Hence, elevated hsCRP levels may indicate a milieu of ongoing adverse remodeling and progressive fibrosis on an already-injured myocardial substrate that combine to predispose to ventricular arrhythmogenesis. Other potential explanations include coronary artery disease progression and ischemia or reactivation of myocardial inflammation.
Limitations
The proposed method of combining patients with chronic ischemic and nonischemic cardiomyopathy in a risk stratification strategy requires further confirmation. There currently is limited histological validation of GZ in either group.
The CMR methodology we used did not assess for diffuse scar, which can occur in nonischemic cardiomyopathies. However, data from preclinical models and explanted human hearts suggest that focal fibrosis, which is best detected by CMR-LGE, is more prone to delayed conduction and, thus, is more arrhythmogenic than diffuse fibrosis. 13, 43 Other studies have used different SI methodology for measuring GZ and core extent in patients with chronic ischemic cardiomyopathy, 10,11 which we did not examine here. There are limited data on the validity of the LGE segmentation approach and its reproducibility in nonischemic cardiomyopathy.
We used cardiac mortality as an end point because of the inherent difficulty in further attributing causality, particularly because autopsies and postmortem ICD interrogations are rarely performed. This strategy minimizes underdetection of events in low-risk groups. However, it may overestimate the benefit of ICD therapy in preventing arrhythmic outcomes in high-risk groups.
Although we excluded patients with acute myocardial infarction within 40 days and those within 3 months of revascularization, time dependency after acute coronary syndromes can potentially modify the effects seen, requiring further investigation. Further investigation is also needed to examine potential effect modifiers in specific nonischemic etiologies. To our knowledge, the relationship between GZ and ventricular arrhythmias has not been studied previously in patients without chronic ischemic cardiomyopathy. We did not examine whether differences in scar morphology in patients with chronic ischemic cardiomyopathy versus patients without chronic ischemic cardiomyopathy were associated with outcome.
Given the observed number of events, we could not perform multivariable modeling against all possible clinical risk markers, so we limited the analysis to parameters found to be significant on univariable analyses. Although we found a very high HR in the highest GZ-CRP tertile, the CI was large. Further, although our prospective cohort study was specifically designed to evaluate the association of CMR parameters with clinical outcomes, the potential importance of the combination of GZ and CRP levels was identified in a post hoc analysis. Future studies should confirm the joint association of GZ and CRP levels on study outcomes and should evaluate their use as prognostic markers in patients who are candidates for a primary prevention ICD. This study does not address the exact mechanism of the complementary prognostic association between GZ and hsCRP, which also requires further investigation. Biomarkers of neurohormonal or sympathetic activation not studied here could also be explored.
Conclusions
The findings suggest a novel approach to SCD risk stratification that uses an index that combines CMR-LGE metrics of tissue heterogeneity and hsCRP indices of inflammation to distinguish very-low-risk from high-risk patients. Future efforts should include prospective randomized controlled trial data of ICD implantation in the Ϸ20% of patients with the lowest tertiles of GZ and hsCRP and evaluating event and complication rates to determine whether ICD therapy can be safely and cost-effectively withheld in this population.
